iMeds.se

Carvanja

Information för alternativet: Carvanja 12,5 Mg Tablett, Carvanja 25 Mg Tablett, Carvanja 6,25 Mg Tablett, visa andra alternativ

Package leaflet: Information for the patient


Carvanja 6.25 mg, 12.5 mg and25 mg tablet


Carvedilol


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.

- If you have any further questions, ask your doctor or pharmacist.

- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.See section 4.


What is in this leaflet


1. What Carvanja is and what it is used for

2. What you need to know before you take Carvanja

3. How to take Carvanja

4. Possible side effects

5. How to store Carvanja

6. Contents of the pack and other information


1. What Carvanja is and what it is used for


Carvanja belongs to the group of drugs, alpha- and beta blockers. Carvanja is used in the treatment of high blood pressure and the treatment of angina pectoris. Carvanja is also used as a supplementary treatment in heart failure.


2. What you need to know before you take Carvanja


Do not take Carvanja:


- if you are allergic to carvedilol or to any of the other ingredients of this medicine (listed in section 6).

- if you have untreated or unstable heart failureor certain types of disturbances in the conduction system of the heart(so-called AV-block of type II and III unless you have a pacemaker, or so-called sick sinus node).

- if you are suffering from a severe liver disease.

- if you have a very low pulse (less than 50 beats per minute)or very low blood pressure.

- if you are suffering from severely compromised cardiac function(cardiogenic shock).

- if you are suffering from serious disturbance in the body’s acid-base balance(metabolic acidosis, acidaemia).

- if you have asthmaor acute obstruction of your respiratory airway.


Warnings and precautions


Talk to your doctor or pharmacist before taking Carvanja.


- if you have heart failure accompanied by

Your renal function should be monitored then. It may be necessary to reduce your dose.

- if you have had a heart attack. This condition must be treated sufficiently before taking Carvanja.

- if you have a certain type of disturbances in the conduction system of the heart(so-called AV-block of type I).

- if you have hypertension due to organic reasons.

- if you have severe breathing problems for which you are not receiving medication, Carvanja may worsen these breathing difficulties.

- if you have diabetes. Treatment with Carvanja may mask the signs of low blood sugar. Your blood sugar should therefore be monitored regularly.

- if you have severely poor blood circulation in the hand and feet.

- if you have Raynaud’s phenomenon (fingers or toes turn first bluish, then whitish and then reddish together with pain). Carvanja may worsen the symptoms.

- if you have over function of thyroid gland, with elevated production of thyroid hormone, Carvanja may mask the symptoms.

- if you are using Carvanja and are to undergo an operationinvolving an anaesthetic. You should discuss this with the doctor responsible for the anaesthesia well in advance.

- if you have a very low pulse (less than 55 beats per minute).

- if you have had a serious allergic reaction(e.g. to an insect bite or food) or if you are undergoing or are due to undergo allergic desensitisation therapy because Carvanja may weaken the efficacy of medicines used to treat such allergic reactions.

- if you have psoriasis.

- if you have an over-function of the adrenal glands(phaeochromocytoma) and this is not being treated with medication.

- if you are suffering from an unusual form of angina pectoris called Prinzmetal’s angina caused by cramping of the coronary arteries.

- if you use contact lenses. Carvanja may reduce tear production.


Other medicines and Carvanja

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Other concomitant drug treatment may affect or be affected by Carvanja.


It is especially important that your doctor be aware if you are already being treated with:


- Digoxinor digitoxin(to treat heart failure).

- Insulinor oral anti-diabetic medicines(blood sugar reducing agents) as their blood sugar reducing effect can be increased and the symptoms of low blood sugar covered up.

- Rifampicin(antibiotic used in treating tuberculosis).

- Carbamazepine(medicine to treat epilepsy).

- Fluconazole(medicine to treat mycosis).

- Paroxetine,fluoxetine, bupropion (medicine to treat depression).

- Drugs containing reserpine, guanetidine, methyldopa, guanfacineand monoaminooxidase inhibitors (MAOIs) (medicinesto treat depression and Parkinson’s disease),as these may give rise to further reduction in the heart rate.

- Ciclosporin(medicine to suppress the immune system, to prevent ejective reactions after organ transplantation also used for e.g., certain rheumatic or dermatological problems).

- Medicines to treat irregular heartbeat (e.g. verapamil, diltiazem, quinidine, amiodarone).

- Clonidine(medicine to reduce blood pressure or to treat migraine).

- Sympathomimetics(drugs which increase the function of the sympathetic nervous system).

- Medicines used to treat breathing problems (e.g. salbutamol, formoterol).

- Dihydropyridines(medicine to treat high blood pressure and heart diseases).

- Other blood pressure reducing drugs. Carvanja can enhance the effects of other blood pressure reducing drugs given concurrently (e.g. alpha1-receptor antagonists, nitrates) and drugs where reduction in blood pressure transpires as a side effect, e.g. barbiturates(in the treatment of epilepsy), phenothiazines(to treat psychoses), tricyclic antidepressants(in the treatment of depression) vasodilating drugs (drugs for widening the blood vessels).

- Neuromuscular blocking preparations(drugs which reduce muscle tension).

- Ergotamine(migraine medicine).

- Anaesthetics (drugs used in anaesthesia).

- Certain painkilling tablets(NSAID), oestrogens(hormones) and corticosteroids(adrenal hormone), as these can in some instances reduce the blood pressure reducing effect of Carvanja.

- Cinacalcet(medicine used to treat problems with parathyroid glands).


Carvanja with alcohol

Carvanja may enhance the effects of alcohol.


Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.


There is a risk of harm to the unborn child. Carvanja should only be used during pregnancy if your doctor deems it necessary. Always, therefore, consult your doctor before using Carvanja during pregnancy.


It is not known whether Carvedilol passes over in human breast milk and should therefore not be used during breastfeeding.


Driving and using machines

Dizziness and tiredness may occur at the beginning of treatment, after dose increase, on changing products or in combination with alcohol. At correct dose levels it is not known whether Carvedilol impairs the ability to drive or use machines. If you feel dizzy or weak when taking the tablets, you should avoid driving or work involving sharp attention.


Carvanja contains lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.


3. How to take Carvanja


Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. If you feel that the effects of Carvanja are too strong or too weak, talk to your doctor or pharmacist.

You should swallow the tablets with at least half a glass of water. You can take the tablets with or without food. Patients with heart failure should however take the tablets with food in order to reduce the risk of dizziness on sudden standing.


The tablets can be divided into equal doses.


Carvanja tablets are available in the following strengths:

6.25 mg, 12.5 mg and 25 mg


High blood pressure:


Adults:

The normal dose is 1 tablet Carvanja 12.5 mg (corresponding to 12.5 mg carvedilol) for the first two days and 2 tablets Carvanja 12.5 mg (corresponding to 25 mg carvedilol) once daily thereafter. For this dosage, other strengths of Carvedilol are available.

If necessary the dose may be further increased graduallyat intervals of at least two weeks.The recommended maximum daily dose is 50 mg.


Older people:

The recommended dose is 1 tablet Carvanja 12.5 mg (corresponding to 12.5 mg carvedilol) once daily.

If necessary, the dose may be further increased gradually at intervals of at least two weeks to the maximum daily dose of 50 mg.


Angina pectoris:


Adults:

The normal dose is 1 tablet Carvanja 12.5 mg (corresponding to 12.5 mg carvedilol twice daily for two days and 2 tablets Carvanja 12.5 mg (corresponding to 25 mg carvedilol) twice daily thereafter. For this dosage, other strengths of Carvanja are available.

If necessary the dose may be further increased graduallyat intervals of at least two weeks. The recommended maximum daily dose is 100 mg.


Older people:

The normal dose is 1 tablet Carvanja 12.5 mg (corresponding to 12.5 mg carvedilol) twice daily for two days and 2 tablets Carvanja 12.5 mg (corresponding to 25 mg carvedilol) twice daily thereafter. The recommended maximum daily dose is 50 mg.


Heart failure:


The normal starting dose is 3.125 mg carvedilol twice daily for two weeks. The dose may be increased incrementally, usually at two week intervals.


The dose may however need to be increased or reduced. Your doctor will advise you accordingly.

The recommended maximum daily dose is 25 mg given twice daily in patients weighing less than 85 kg and 50 mg twice daily in patients weighing more than 85 kg, provided that heart failure is not severe. A dose increase to 50 mg twice daily should be performed carefully under close medical supervision.


If you take more Carvanja than you should

If you have taken more Carvanja than you should, or if children have been taking medicine by accident, please contact your doctor, the hospital or call the emergency to get an opinion of the risk and advice on action to be taken.

Symptoms of overdose can include feelings of faintness due to excessively low blood pressure, slow heart rate and in serious instances occasional missed heartbeats. Breathing difficulties, constricted airways, malaise, lowered level of consciousness and seizures may occur.


If you forget to take Carvanja

If you forget a dose (or more doses), take the next dose when it is the normal time to take it. Do not take a double (or a larger) dose to make up with the forgotten dose(s).


If you stop taking Carvanja

Do not suddenly stop your treatment or change the dose unless instructed by your doctor. Your treatment should be phased out gradually over a period of two weeks. Any sudden discontinuation can make your symptoms worse.


If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


4. Possible side effects


Like all medicines, this medicine can cause side effects, although not everybody gets them.


The majority of side effects are dose-related and disappear when the dose is reduced or the treatment discontinued. Some side effects can occur at the beginning of treatment and resolve spontaneously as the treatment continues.


Very common (may affect more than 1 in 10 people):


Common (may affect up to 1 in 10 people):


Uncommon (may affect up to 1 in 100 people):


Rare (may affect up to 1 in 1,000people):


Very rare(may affect up to1 in 10,000 people, including isolated cases):


Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet.You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

[To be completed nationally]


5. How to store Carvanja


Keep this medicine out of the sight and reach of children.


Do not use this medicine after the expiry date which is stated on the labelafter EXP. The expiry date refers to the last day of that month.


Blister (PVC/PVdC-Aluminium)

6.25 mg:

Do not store above 30°C.

Store in the original package in order to protect from light.

12.5 mg and 25 mg:

Store in the original package in order to protect from light.

This medicinal product does not require any special temperature storage conditions.


Blister (OPA/Aluminium/PVC-Aluminium)

Store in the original package in order to protect from light.

This medicinal product does not require any special temperature storage conditions.


Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


6. Contents of the pack and other information


What Carvanja contains


The active substance is carvedilol.

Each tablet contains 6.25/12.5/25 mg of carvedilol.


The other ingredients are cellulose microcrystalline, lactose monohydrate, crospovidone, povidone, silica, colloidal anhydrous, magnesium stearate.


What Carvanja looks like and contents of the pack


6.25 mg tablets: white, biconvex, capsule shaped tablets debossed “C” with breakline and “2” on one side and plain on the other.

12.5 mg tablets: white, biconvex, capsule shaped tablets debossed “C” with breakline and “3” on one side and plain on the other.

25 mg tablets: white, biconvex, capsule shaped tablets debossed “C” with breakline and “4” on one side and plain on the other


The tablets can be divided into equal doses.


Pack sizes: 10, 14, 28, 30, 50, 56, 60, 98 and 100 tablets.

Not all pack sizes may be marketed.


Marketing Authorisation Holder and Manufacturer


[To be completed nationally]


This medicinal product is authorisedin the Member States of the EEA under the following names:


Schweden: Carvanja 6,25/12,5/25 mg tabletter

Germany: CarvedilolCT 6,25/12,5/25 mg Tabletten


This leaflet was last revised in 23 November 2015